Genetic control of innate immune responses against cytomegalovirus: MCMV meets its match

Genes and Immunity

Volumn 3, Issue 5, 2002, Pages 250-262

  Webb, J R ^a   Lee, S H ^a   Vidal, S M ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Ly49 receptors; Murine cytomegalovirus; Natural killer cells

Indexed keywords

LIGAND; LYSINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE RECEPTOR; VIRUS PROTEIN; LECTIN; LY 49 ANTIGEN; LY ANTIGEN; LY-49 ANTIGEN;

ALLELE; ANTIGEN EXPRESSION; CELL ACTIVATION; CELL FUNCTION; CELL KILLING; CELL SURFACE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE SEVERITY; GENE IDENTIFICATION; GENE LOCUS; GENE MAPPING; GENETIC ANALYSIS; GENETIC REGULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION RESISTANCE; INFECTION SENSITIVITY; MOUSE; MULTIGENE FAMILY; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; TARGET CELL; VASCULAR DISEASE; VIRUS REPLICATION; ANIMAL; BIOLOGICAL MODEL; CHROMOSOME MAP; CYTOMEGALIC INCLUSION BODY DISEASE; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MOLECULAR CLONING; PHYSIOLOGY; VIROLOGY;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

ANIMALS; ANTIGENS, LY; CHROMOSOME MAPPING; CLONING, MOLECULAR; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, NATURAL; KILLER CELLS, NATURAL; LECTINS, C-TYPE; MICE; MODELS, IMMUNOLOGICAL; VIRUS REPLICATION;

EID: 0036691458     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6363876     Document Type: Review

References (153)

1. Britt W, Alford CA. Cytomegalovirus. In: Fields BN (eds). Fields Virology. Lippincott-Raven: New York, 1996, pp 2493-2523.
2. Rawlinson WD. Broadsheet. Number 50: diagnosis of human cytomegalovirus infection and disease. Pathology 1999; 31: 109-115.
3. Soderberg-Naucler C, Nelson JY. Human cytomegalovirus latency and reactivation - a delicate balance between the virus and its host's immune system. Intervirology 1999; 42: 314-321.
4. Reusser P. Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients. Support Care Cancer 1998; 6: 39-45.
5. Reusser P, Attenhofer R, Hebart H, Helg C, Chapuis B, Einsele H. Cytomegalovirus-specific T-cell immunity in recipients of autologous peripheral blood stem cell or bone marrow transplants. Blood 1997; 89: 3873-3879.
6. Soderberg-Naucler C, Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 2001; 71: SS24-SS30.
7. Trincado DE, Scott GM, White PA, Hunt C, Rasmussen L, Rawlinson WD. Human cytomegalovirus strains associated with congenital and perinatal infections. J Med Virol 2000; 61: 481-487.
8. Demmler GJ. Infectious Diseases Society of America and Centers for Disease Control. Summary of a workshop on surveillance for congenital cytomegalovirus disease. Rev Infect Dis 1991; 13: 315-329.
9. Hurme M, Helminen M. Resistance to human cytomegalovirus infection may be influenced by genetic polymorphisms of the tumour necrosis factor-alpha and interleukin-1 receptor antagonist genes. Scand J Infect Dis 1998; 30: 447-449.
10. Kaufman DB, Leventhal JR, Gallon LG et al. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation. Transplantation 2001; 72: 1940-1945.
11. Singh N, Wagener MM, Gayowski T. Seasonal pattern of early mortality and infectious complications in liver transplant recipients. Liver Transpl 2001; 7: 884-889.
12. Nachbaur D, Bonatti H, Oberaigner W et al. Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet 2001; 358: 1157-1159.
13. Farmer DG, McDiarmid SV, Yersiz H et al. Outcome after intestinal transplantation: results from one center's 9-year experience; discussion 1031-2. Arch Surg 2001; 136: 1027-1031.
14. Rubin RH. Importance of CMV in the transplant population. Transpl Infect Dis 1999; 1 (Suppl 1): 3-7.
15. de Medeiros CR, Moreira VA, Pasquini R. Cytomegalovirus as a cause of very late interstitial pneumonia after bone marrow transplantation. Bone Marrow Transplant 2000; 26: 443-444.
16. Sparrelid E, Emanuel D, Fehniger T, Andersson U, Andersson J. Interstitial pneumonitis in bone marrow transplant recipients is associated with local production of TH2-type cytokines and lack of T cell-mediated cytotoxicity. Transplantation 1997; 63: 1782-1789.
17. Stratta RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 1993; 25: 15-21.
18. Tolkoff-Rubin NE, Rubin RH. Viral infections in organ transplantation. Transplant Proc 1998; 30: 2060-2063.
19. Snydman DR. Infection in solid organ transplantation. Transpl Infect Dis 1999; 1: 21-28.
20. Yamada S, Takatsuka H, Takemoto Y et al. Association of cytomegalovirus interstitial pneumonitis with HLA-type following allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 25: 861-865.
21. Salmon-Ceron D. Cytomegalovirus infection: the point in 2001. HIV Med 2001; 2: 255-259.
22. Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.
23. Welch K, Kissinger P, Bessinger R, Dascomb K, Morse A, Gleckler E. The clinical profile of end-stage AIDS. AIDS Patient Care STDS 1998; 12: 125-129.
24. Vercellotti GM. Overview of infections and cardiovascular diseases. J Allergy Clin Immunol 2001; 108: S117-S120.
25. Levi M. CMV endothelitis as a factor in the pathogenesis of atherosclerosis. Cardiovasc Res 2001; 50: 432-433.
26. Valantine HA. Role of CMV in transplant coronary artery disease and survival after heart transplantation. Transpl Infect Dis 1999; 1 (Suppl 1): 25-30.
27. Zhou YF, Leon MB, Waclawiw MA et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-630.
28. Neumann FJ, Kastrati A, Miethke T et al. Previous cytomegalovirus infection and restenosis after coronary stent placement. Circulation 2001; 104: 1135-1139.
29. Koskinen PK, Kallio EA, Tikkanen JM, Sihvola RK, Hayry PJ, Lemstrom KB. Cytomegalovirus infection and cardiac allograft vasculopathy. Transpl Infect Dis 1999; 1: 115-126.
30. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet 1996; 348 (Suppl 1): s13-s17.
31. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis 2001; 156: 23-28.
32. Burnett MS, Gaydos CA, Madico GE et al. Atherosclerosis in apoE knockout mice infected with multiple pathogens. J Infect Dis 2001; 183: 226-231.
33. Fabricant CG, Fabricant J. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. Am Heart J 1999; 138: S465-S468.
34. Villarreal EC. Current and potential therapies for the treatment of herpesvirus infections. Prog Drug Res 2001; 56: 185-228.
35. Zaia JA, Sissons JG, Riddell S et al. Status of cytomegalovirus prevention and treatment in 2000. Hematology (Am Soc Hematol Educ Program) 2000; 1: 339-355.
36. Chou S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1999; 1: 105-114.
37. Emery VC. Progress in understanding cytomegalovirus drug resistance. J Clin Virol 2001; 21: 223-228.
38. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17: 189-220.
39. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989; 47: 187-376.
40. Tay CH, Szomolanyi-Tsuda E, Welsh RM. Control of infections by NK cells. Curr Top Microbiol Immunol 1998; 230: 193-220.
41. Venema H, van den Berg AP, van Zanten C, van Son WJ, van der GM, The TH. Natural killer cell responses in renal transplant patients with cytomegalovirus infection. J Med Virol 1994; 42: 188-192.
42. Slavin M, Dobbs S, Crawford S, Bowden R. Interleukin-2, interferon-gamma and natural killer cell activity in bronchoalveolar lavage fluid from marrow transplant recipients with cytomegalovirus pneumonia. Bone Marrow Transplant 1993; 11: 113-118.
43. Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 1989; 320: 1731-1735.
44. Sullivan JL, Woda BA. X-linked lymphoproliferative syndrome. Immunodefic Rev 1989; 1: 325-347.
45. Coffey AJ, Brooksbank RA, Brandau O et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998; 20: 129-135.
46. Sayos J, Wu C, Morra M et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998; 395: 462-469.
47. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol 1999; 162: 6981-6985.
48. Parolini S, Bottino C, Falco M et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000; 192: 337-346.
49. Sayos J, Nguyen KB, Wu C et al. Potential pathways for regulation of NK and T cell responses: differential X-linked lymphoproliferative syndrome gene product SAP interactions with SLAM and 2B4. Int Immunol 2000; 12: 1749-1757.
50. Shanley JD. Host genetic factors influence murine cytomegalovirus lung infection and interstitial pneumonitis. J Gen Virol 1984; 65: 2121-2128.
51. Trgovcich J, Stimac D, Polic B et al. Immune responses and cytokine induction in the development of severe hepatitis during acute infections with murine cytomegalovirus. Arch Virol 2000; 145: 2601-2618.
52. Hayashi K, Suwa Y, Shimomura Y, Ohashi Y. Pathogenesis of ocular cytomegalovirus infection in the immunocompromised host. J Med Virol 1995; 47: 364-369.
53. Hayashi K, Kurihara I, Uchida Y. Studies of ocular murine cytomegalovirus infection. Invest Ophthalmol Vis Sci 1985; 26: 486-493.
54. Shanley JD, Biczak L, Forman SJ. Acute murine cytomegalovirus infection induces lethal hepatitis. J Infect Dis 1993; 167: 264-269.
55. Shellam GR, Flexman JP. Genetically determined resistance to murine cytomegalovirus and herpes simplex virus in newborn mice. J Virol 1986; 58: 152-156.
56. Fitzgerald NA, Shellam GR. Host genetic influences on fetal susceptibility to murine cytomegalovirus after maternal or fetal infection. J Infect Dis 1991; 163: 276-281.
57. Allan JE, Shellam GR. Genetic control of murine cytomegalovirus infection: virus titres in resistant and susceptible strains of mice. Arch Virol 1984; 81: 139-150.
58. Shanley JD. Host genetic factors influence murine cytomegalovirus lung infection and interstitial pneumonitis. J Gen Virol 1984; 65: 2121-2128.
59. Biron CA, Brossay L. NK cells and NKT cells in innate defense against viral infections. Curr Opin Immunol 2001; 13: 458-464.
60. Scalzo AA, Fitzgerald NA, Wallace CR et al. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J Immunol 1992; 149: 581-589.
61. Bukowski JF, Welsh RM. The role of natural killer cells and interferon in resistance to acute infection of mice with herpes simplex virus type 1. J Immunol 1986; 136: 3481-3485.
62. Welsh RM, Brubaker JO, Vargas-Cortes M, O'Donnell CL. Natural killer (NK) cell response to virus infections in mice with severe combined immunodeficiency. The stimulation of NK cells and the NK cell-dependent control of virus infections occur independently of T and B cell function. J Exp Med 1991; 173: 1053-1063.
63. Ellison AR, Yang L, Voytek C, Margolis TP. Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains. Virology 2000; 268: 17-28.
64. Riera L, Gariglio M, Valente G et al. Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection. Eur J Immunol 2000; 30: 1350-1355.
65. Tsunobuchi H, Nishimura H, Goshima F et al. A protective role of interleukin-15 in a mouse model for systemic infection with herpes simplex virus. Virology 2000; 275: 57-66.
66. Pien GC, Satoskar AR, Takeda K, Akira S, Biron CA. Cutting edge: selective IL-18 requirements for induction of compart-mental IFN-gamma responses during viral infection. J Immunol 2000; 165: 4787-4791.
67. Carr JA, Rogerson JA, Mulqueen MJ, Roberts NA, Nash AA. The role of endogenous interleukin-12 in resistance to murine cytomegalovirus (MCMV) infection and a novel action for endogenous IL-12 p40. J Interferon Cytokine Res 1999; 19: 1145-1152.
68. Dutia BM, Allen DJ, Dyson H, Nash AA. Type 1 interferons and IRF-1 play a critical role in the control of a gammaherpesvirus infection. Virology 1999; 261: 173-179.
69. Fernandez JA, Rodrigues EG, Tsuji M. Multifactorial protective mechanisms to limit viral replication in the lung of mice during primary murine cytomegalovirus infection. Viral Immunol 2000; 13: 287-295.
70. Kumaraguru U, Davis IA, Deshpande S, Tevethia SS, Rouse BT. Lymphotoxin alpha -/- mice develop functionally impaired CD8+ T cell responses and fail to contain virus infection of the central nervous system. J Immunol 2001; 166: 1066-1074.
71. Salazar-Mather TP, Orange JS, Biron CA. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1 alpha (MIP-1 alpha)-dependent pathways. J Exp Med 1998; 187: 1-14.
72. Rager-Zisman B, Quan PC, Rosner M, Moller JR, Bloom BR. Role of NK cells in protection of mice against herpes simplex virus-1 infection. J Immunol 1987; 138: 884-888.
73. Ghiasi H, Cai S, Perng G, Nesburn AB, Weschsler SL. Perforin pathway is essential for protection of mice against lethal ocular HSV-1 challenge but not corneal scarring. Virus Res 1999; 65: 97-101.
74. MacLean A, Wei XQ, Huang FP, Al Alem UA, Chan WL, Liew FY. Mice lacking inducible nitric-oxide synthase are more susceptible to herpes simplex virus infection despite enhanced Th1 cell responses. J Gen Virol 1998; 79: 825-830.
75. Morra M, Howie D, Grande MS et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol 2001; 19: 657-682.
76. Wu C, Nguyen KB, Pien GC et al. SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol 2001; 2: 410-414.
77. Lee SH, Girard S, Macina D et al. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat Genet 2001; 28: 42-45.
78. Brown MG, Dokun AO, Heusel JW et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 2001; 292: 934-937.
79. Shellam GR, Allan JE, Papadimitriou JM, Bancroft GJ. Increased susceptibility to cytomegalvirus infection in beige mutant mice. Proc Natl Acad Sci USA 1981; 78: 5104-5108.
80. Barbosa MD, Nguyen QA, Tchernev VT et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 1996; 382: 262-265.
81. Chalmer JE, Mackenzie JS, Stanley NF. Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse. J Gen Virol 1977; 37: 107-114.
82. Grundy JE, Mackenzie JS, Stanley NF. Influence of H-2 and non-H-2 genes on resistance to murine cytomegalovirus infection. Infect Immun 1981; 32: 277-286.
83. Price P, Winter JG, Nikoletti S, Hudson JB, Shellam GR. Functional changes in murine macrophages infected with cytomegalvirus relate to H-2-determined sensitivity to infection. J Virol 1987; 61: 3602-3606.
84. Wykes MN, Shellam GR, McCluskey J, Kast WM, Dallas PB, Price P. Murine cytomegalovirus interacts with major histocompatibility complex class I molecules to establish cellular infection. J Virol 1993; 67: 4182-4189.
85. Scalzo AA, Fitzgerald NA, Simmons A, La Vista AB, Shellam GR. Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J Exp Med 1990; 171: 1469-1483.
86. Price P, Olver SD, Gibbons AE, Teo HK, Shellam GR. Characterization of thymic involution induced by murine cytomegalovirus infection. Immunol Cell Biol 1993; 71: 155-165.
87. Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2001; 2: 951-956.
88. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997; 71: 267-275.
89. Brown MG, Fulmek S, Matsumoto K et al. A 2-Mb YAC contig and physical map of the natural killer gene complex on mouse chromosome 6. Genomics 1997; 42: 16-25.
90. Newmark PA. Boswell RE. The mago nashi locus encodes an essential product required for germ plasm assembly in Drosophila. Development 1994; 120: 1303-1313.
91. Coles LS, Diamond P, Occhiodoro F, Vadas MA, Shannon MF. Cold shock domain proteins repress transcription from the GM-CSF promoter. Nucleic Acids Res 1996; 24: 2311-2317.
92. Adler E, Hoon MA, Mueller KL, Chandrashekar J, Ryba NJ, Zuker CS. A novel family of mammalian taste receptors. Cell 2000; 100: 693-702.
93. Maeda N, Kim HS, Azen EA, Smithies O. Differential RNA splicing and post-translational cleavages in the human salivary proline-rich protein gene system. J Biol Chem 1985; 260: 11123-11130.
94. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001; 19: 291-330.
95. Ryan JC, Turck J, Niemi EC, Yokoyama WM, Seaman WE. Molecular cloning of the NK1. 1 antigen, a member of the NKR-P1 family of natural killer cell activation molecules. J Immunol 1992; 149: 1631-1635.
96. Yi T, Gilbert DJ, Jenkins NA, Copeland NG, Ihle JN. Assignment of a novel protein tyrosine phosphatase gene (Hcph) to mouse chromosome 6. Genomics 1992; 14: 793-795.
97. Westgaard IH, Berg SF, Orstavik S, Fossum S, Dissen E. Identification of a human member of the Ly-49 multigene family. Eur J Immunol 1998; 28: 1839-1846.
98. Barten R, Torkar M, Haude A, Trowsdale J, Wilson MJ. Divergent and convergent evolution of NK-cell receptors. Trends Immunol 2001; 22: 52-57.
99. Wilson MJ, Torkar M, Haude A et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci USA 2000; 97: 4778-4783.
100. Biassoni R, Pessino A, Bottino C, Pende D, Moretta L, Moretta A. The murine homologue of the human NKp46, a triggering receptor involved in the induction of natural cytotoxicity. Eur J Immunol 1999; 29: 1014-1020.
101. Kubagawa H, Cooper MD, Chen CC et al. Paired immunoglobulin-like receptors of activating and inhibitory types. Curr Top Microbiol Immunol 1999; 244: 137-149.
102. Idris AH, Iizuka K, Smith HR, Scalzo AA, Yokoyama WM. Genetic control of natural killing and in vivo tumor elimination by the Chok locus. J Exp Med 1998; 188: 2243-2256.
103. Beebe AM, Mauze S, Schork NJ, Coffman RL. Serial backcross mapping of multiple loci associated with resistance to Leishmania major in mice. Immunity 1997; 6: 551-557.
104. Melanitou E, Joly F, Lathrop M, Boitard C, Avner P. Evidence for the presence of insulin-dependent diabetes-associated alleles on the distal part of mouse chromosome 6. Genome Res 1998; 8: 608-620.
105. Delano ML, Brownstein DG. Innate resistance to lethal mouse-pox is genetically linked to the NK gene complex on chromosome 6 and correlates with early restriction of virus replication by cells with an NK phenotype. J Virol 1995; 69: 5875-5877.
106. Dissen E, Ryan JC, Seaman WE, Fossum S. An autosomal dominant locus, Nka, mapping to the Ly-49 region of a rat natural killer (NK) gene complex, controls NK cell lysis of allogeneic lymphocytes. J Exp Med 1996; 183: 2197-2207.
107. Jansson AM, Jacobsson L, Luthman H, Lorentzen JC. Susceptibility to oil-induced arthritis linked to Oia2 on chromosome 4 in a DA(DA x PVG.1AV1) backcross. Transplant Proc 1999; 31: 1597-1599.
108. Ikeda H, Lethe B, Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997; 6: 199-208.
109. Yen JH, Moore BE, Nakajima T et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001; 193: 1159-1167.
110. Depatie C, Muise E, Lepage P, Gross P, Vidal SM. High-resolution linkage map in the proximity of the host resistance locus Cmv1. Genomics 1997; 39: 154-163.
111. Depatie C, Chalifour A, Pare C, Lee SH, Vidal SM, Lemieux S. Assessment of Cmv1 candidates by genetic mapping and in vivo antibody depletion of NK cell subsets. Int Immunol 1999; 11: 1541-1551.
112. Depatie C, Lee SH, Stafford A et al. Sequence-ready BAC contig, physical, and transcriptional map of a 2-Mb region overlapping the mouse chromosome 6 host-resistance locus Cmv1. Genomics 2000; 66: 161-174.
113. Melanitou E, Simon-Chazottes D, Guenet JL, Rougeon F. The gene coding for the kidney androgen-regulated protein (Kap), maps between the Gapd and Kras-2 genes on mouse chromosome 6. Mamm Genome 1991; 1: 191-192.
114. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994; 77: 307-316.
115. Brown MG, Zhang J, Du Y, Stoll J, Yokoyama WM, Scalzo AA. Localization on a physical map of the NKC-linked Cmv1 locus between Ly49b and the Prp gene cluster on mouse chromosome 6. J Immunol 1999; 163: 1991-1999.
116. Brennan J, Lemieux S, Freeman JD, Mager DL, Takei F. Heterogeneity among Ly-49C natural killer (NK) cells: characterization of highly related receptors with differing functions and expression patterns. J Exp Med 1996; 184: 2085-2090.
117. Makrigiannis AP, Anderson SK. Ly49 gene expression in different inbred mouse strains. Immunol Res 2000; 21: 39-47.
118. Lee SH, Gitas J, Zafer A et al. Haplotype mapping indicates two independent origins for the Cmv1s susceptibility allele to cytomegalovirus infection and refines its localization within the Ly49 cluster. Immunogenetics 2001; 53: 501-505.
119. Brown MG, Scalzo AA, Stone LR et al. Natural killer gene complex (Nkc) allelic variability in inbred mice: evidence for Nkc haplotypes. Immunogenetics 2001; 53: 584-591.
120. Makrigiannis AP, Pau AT, Saleh A, Winkler-Pickett R, Ortaldo JR, Anderson SK. Class I mhc-binding characteristics of the 129/j ly49 repertoire. J Immunol 2001; 166: 5034-5043.
121. Taylor BA, Wnek C, Kotlus BS, Roemer N, Mac Taggart T, Phillips SJ. Genotyping new BXD recombinant inbred mouse strains and comparison of BXD and consensus maps. Mamm Genome 1999; 10: 335-348.
122. Daniels KA, Devora G, Lai WC, O'Donnell CL, Bennett M, Welsh RM. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J Exp Med 2001; 194: 29-44.
123. Anderson SK, Ortaldo JR, McVicar DW. The ever-expanding Ly49 gene family: repertoire and signaling. Immunol Rev 2001; 181: 79-89.
124. Ortaldo JR, Winkler-Pickett R, Mason AT, Mason LH. The Ly-49 family: regulation of cytotoxicity and cytokine production in murine CD3+ cells. J Immunol 1998; 160: 1158-1165.
125. Mason LH, Gosselin P, Anderson SK, Fogler WE, Ortaldo JR, McVicar DW. Differential tyrosine phosphorylation of inhibitory versus activating Ly-49 receptor proteins and their recruitment of SHP-1 phosphatase. J Immunol 1997; 159: 4187-4196.
126. Nakamura MC, Niemi EC, Fisher MJ, Shultz LD, Seaman WE, Ryan JC. Mouse Ly-49A interrupts early signaling events in natural killer cell cytotoxicity and functionally associates with the SHP-1 tyrosine phosphatase. J Exp Med 1997; 185: 673-684.
127. Mason LH, Ortaldo JR, Young HA, Kumar V, Bennett M, Anderson SK. Cloning and functional characteristics of murine large granular lymphocyte-1: a member of the Ly-49 gene family (Ly-49G2). J Exp Med 1995; 182: 293-303.
128. Kase A, Johansson MH, Olsson-Alheim MY, Karre K, Hoglund P. External and internal calibration of the MHC class I-specific receptor Ly49A on murine natural killer cells. J Immunol 1998; 161: 6133-6138.
129. Andersson M, Freland S, Johansson MH et al. MHC class I mosaic mice reveal insights into control of Ly49C inhibitory receptor expression in NK cells. J Immunol 1998; 161: 6475-6479.
130. Tormo J, Natarajan K, Margulies DH, Mariuzza RA. Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature 1999; 402: 623-631.
131. Natarajan K, Boyd LF, Schuck P, Yokoyama WM, Eliat D, Margulies DH. Interaction of the NK cell inhibitory receptor Ly49A with H-2Dd: identification of a site distinct from the TCR site. Immunity 1999; 11: 591-601.
132. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 1998; 391: 703-707.
133. Mason LH, Willette-Brown J, Mason AT, McVicar D, Ortaldo JR. Interaction of Ly-49D+NK cells with H-2Dd target cells leads to Dap-12 phosphorylation and IFN-gamma secretion. J Immunol 2000; 164: 603-611.
134. Lanier LL, Bakker AB. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol Today 2000; 21: 611-614.
135. Paloneva J, Kestila M, Wu J et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet 2000; 25: 357-361.
136. Nakamura MC, Seaman WE. Ligand interactions by activating and inhibitory Ly-49 receptors. Immunol Rev 2001; 181: 138-148.
137. Idris AH, Smith HR, Mason LH, Ortaldo JR, Scalzo AA, Yokoyama WM. The natural killer gene complex genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing. Proc Natl Acad Sci USA 1999; 96: 6330-6335.
138. Ortaldo JR, Bere EW, Hodge D, Young HA. Activating Ly-49 NK receptors: central role in cytokine and chemokine production. J Immunol 2001; 166: 4994-4999.
139. Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675-678.
140. Farrell HE, Vally H, Lynch DM et al. Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 1997; 386: 510-514.
141. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev 2001; 1: 41-49.
142. Alcami A, Koszinowski UH. Viral mechanisms of immune evasion. Immunol Today 2000; 21: 447-455.
143. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988; 331: 269-272.
144. Fahnestock ML, Johnson JL, Feldman RM, Neveu JM, Lane WS, Bjorkman PJ. The MHC class I homolog encoded by human cytomegalovirus binds endogenous peptides. Immunity 1995; 3: 583-590.
145. Leong CC, Chapman TL, Bjorkman PJ et al. Modulation of natural killer cell cytotoxicity in human cytomegalovirus infection: the role of endogenous class I major histocompatibility complex and a viral class I homolog. J Exp Med 1998; 187: 1681-1687.
146. Cosman D, Fanger N, Borges L et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 1997; 7: 273-282.
147. Yokoyama WM. Now you see it, now you don't! Nat Immunol 2000; 1: 95-97.
148. Wu J, Song Y, Bakker AB et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730-732.
149. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2001; 2: 255-260.
150. Bauer S, Groh V, Wu J et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
151. Cosman D, Mullberg J, Sutherland CL et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133.
152. Cerwenka A, Bakker AB, McClanahan T et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000; 12: 721-727.
153. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000; 1: 119-126.